Objective: Aim was to identify hypotheses why adverse neurodevelopment still occurs in children with transient or persistent hyperinsulinism despite improvements in long-term treatment options during the last decades. Material and Methods: A retrospective review of 87 children with transient (n=37) or persistent congenital hyperinsulinism (CHI) (n=50) was conducted at the University Children's Hospital Duesseldorf, Germany. Possible risk factors for neurodevelopmental sequelae due to hypoglycemia were analyzed with a focus on the first days after onset of disease. Results: Median age at follow-up was 7 years (IQR 8). Adverse neurodevelopmental outcome was seen in 34.5% (n=30) of all CHI patients. Fifteen had mildly abnormal neurodevelopment and 15 had a severe hypoglycemic brain injury. In univariate analysis, mildly abnormal neurodevelopment was associated with the diagnosis of persistent CHI (odds ratio (OR) 8.3; p=0.004) and higher birth weight (mean difference 1049 g; p<0.001). Severe hypoglycemic brain injury was associated with the diagnosis of persistent CHI (OR 5.1; p=0.013), being born abroad (OR 18.3; p<0.001) or in a lower-level maternity hospital (OR 4.8; p=0.039), and of note history of hypoglycemic seizures (OR 13.0; p=<0.001), and a delay between first symptoms of hypoglycemia and first blood glucose measurement/initiation of treatment (OR 10.7; p<0.001). Children with severe hypoglycemic brain injury had lower recorded blood glucose (mean difference -8.34 mg/dl; p=0.022) and higher birth weight than children with normal development (mean difference 829 g; p=0.012). In multivariate binary logistic regression models, lowest blood glucose <20 mg/dl (OR 134.3; p=0.004), a delay between initial symptoms and first blood glucose measurement/initiation of treatment (OR 71.7; p=0.017) and hypoglycemic seizures (OR 12.9; p=0.008) were positively correlated with severe brain injury. Analysis showed that the odds for brain injury decreased by 15% (OR 0.85; p=0.035) if the blood glucose increased by one unit. Conclusion: While some risk factors for adverse outcome in CHI are not influenceable, others like lowest recorded blood glucose values <20 mg/dl, hypoglycemic seizures, and insufficiently-or even untreated hypoglycemia can be avoided. Future guidelines for management of neonatal hypoglycemia should address this by ensuring early identification and immediate treatment with appropriate escalation steps.
Objective: Aim was to identify hypotheses why adverse neurodevelopment still occurs in children with transient or persistent hyperinsulinism despite improvements in long-term treatment options during the last decades. Material and Methods: A retrospective review of 87 children with transient (n=37) or persistent congenital hyperinsulinism (CHI) (n=50) was conducted at the University Children's Hospital Duesseldorf, Germany. Possible risk factors for neurodevelopmental sequelae due to hypoglycemia were analyzed with a focus on the first days after onset of disease. Results: Median age at follow-up was 7 years (IQR 8). Adverse neurodevelopmental outcome was seen in 34.5% (n=30) of all CHI patients. Fifteen had mildly abnormal neurodevelopment and 15 had a severe hypoglycemic brain injury. In univariate analysis, mildly abnormal neurodevelopment was associated with the diagnosis of persistent CHI (odds ratio (OR) 8.3; p=0.004) and higher birth weight (mean difference 1049 g; p<0.001). Severe hypoglycemic brain injury was associated with the diagnosis of persistent CHI (OR 5.1; p=0.013), being born abroad (OR 18.3; p<0.001) or in a lower-level maternity hospital (OR 4.8; p=0.039), and of note history of hypoglycemic seizures (OR 13.0; p=<0.001), and a delay between first symptoms of hypoglycemia and first blood glucose measurement/initiation of treatment (OR 10.7; p<0.001). Children with severe hypoglycemic brain injury had lower recorded blood glucose (mean difference -8.34 mg/dl; p=0.022) and higher birth weight than children with normal development (mean difference 829 g; p=0.012). In multivariate binary logistic regression models, lowest blood glucose <20 mg/dl (OR 134.3; p=0.004), a delay between initial symptoms and first blood glucose measurement/initiation of treatment (OR 71.7; p=0.017) and hypoglycemic seizures (OR 12.9; p=0.008) were positively correlated with severe brain injury. Analysis showed that the odds for brain injury decreased by 15% (OR 0.85; p=0.035) if the blood glucose increased by one unit. Conclusion: While some risk factors for adverse outcome in CHI are not influenceable, others like lowest recorded blood glucose values <20 mg/dl, hypoglycemic seizures, and insufficiently-or even untreated hypoglycemia can be avoided. Future guidelines for management of neonatal hypoglycemia should address this by ensuring early identification and immediate treatment with appropriate escalation steps.
Authors: Christopher J D McKinlay; Jane M Alsweiler; Nicola S Anstice; Nataliia Burakevych; Arijit Chakraborty; J Geoffrey Chase; Gregory D Gamble; Deborah L Harris; Robert J Jacobs; Yannan Jiang; Nabin Paudel; Ryan J San Diego; Benjamin Thompson; Trecia A Wouldes; Jane E Harding Journal: JAMA Pediatr Date: 2017-10-01 Impact factor: 16.193
Authors: Jeffrey R Kaiser; Shasha Bai; Neal Gibson; Greg Holland; Tsai Mei Lin; Christopher J Swearingen; Jennifer K Mehl; Nahed O ElHassan Journal: JAMA Pediatr Date: 2015-10 Impact factor: 16.193
Authors: Liisa Muukkonen; Jonna Männistö; Jarmo Jääskeläinen; Riitta Hannonen; Hanna Huopio Journal: Dev Med Child Neurol Date: 2018-09-23 Impact factor: 5.449
Authors: Annett Helleskov; Maria Melikyan; Evgenia Globa; Inna Shcherderkina; Fani Poertner; Anna-Maria Larsen; Karen Filipsen; Klaus Brusgaard; Charlotte Dahl Christiansen; Lars Kjaersgaard Hansen; Henrik T Christesen Journal: Front Endocrinol (Lausanne) Date: 2017-07-10 Impact factor: 5.555
Authors: Hima Bindu Avatapalle; Indraneel Banerjee; Sajni Shah; Megan Pryce; Jacqueline Nicholson; Lindsey Rigby; Louise Caine; Mohammed Didi; Mars Skae; Sarah Ehtisham; Leena Patel; Raja Padidela; Karen E Cosgrove; Mark J Dunne; Peter E Clayton Journal: Front Endocrinol (Lausanne) Date: 2013-05-20 Impact factor: 5.555
Authors: Henrike Hoermann; Marcia Roeper; Roschan Salimi Dafsari; Felix Koestner; Dominik Schneble; Dunja von Zezschwitz; Ertan Mayatepek; Sebastian Kummer; Thomas Meissner Journal: BMJ Open Date: 2022-08-19 Impact factor: 3.006